Medical device co IceCure plans Tel Aviv IPO
The company plans to raise NIS 30 million.
The company's first product is for the removal of benign growths from the breast. The product obtained US Food and Drug Administration approval last year, and it is also approved for sale in Europe.
Among IceCure's shareholders are Giza (33%), Docor (16%), and Ofer Hi-Tech (11%.
Published by Globes [online], Israel business news - www.globes-online.com - on January 5, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options